Table 2.

Concordance metrics between (A) the Mindray CL-900i anti-SARS-CoV-2 IgG testing and the Roche Elecsys Anti SARS-CoV-2 testing, (B) the VidasIII anti-SARS-CoV-2 IgG testing and the Roche Elecsys Anti SARS-CoV-2 testing, and (C) the BioMérieux VidasIII anti-SARS-CoV-2 IgG testing and the Mindray CL-900i anti-SARS-CoV-2 IgG testing.

	Roche Elecsys anti SARS-CoV-2			Overall percent agreement	Positive percent agreement	Negative percent agreement	Cohen’s kappa statistic
	Positive	Negative	Total	% (95 CI)	% (95 CI)	% (95 CI)	k (95% CI)
(A) Mindray CL-900i anti-SARS-CoV-2 IgG
Positive	155	14	169	93.4% (90.5–95.5%)	92.8% (87.9–95.8%)	93.8% (89.9–96.3%)	0.87 (0.83–0.90)
Negative	12	213	225
Total	167	227	394
(B) BioMérieux VidasIII anti-SARS-CoV-2 IgG
Positive	155	5	160	95.7% (93.2–97.3%)	92.8% (87.9–95.8%)	97.8% (95.0–99.1%)	0.91 (0.88–0.94)
Negative	12	222	234
Total	167	227	394

	Mindray CL-900i anti-SARS-CoV-2 IgG			Overall percent agreement	Positive percent agreement	Negative percent agreement	Cohen’s kappa statistic
	Positive	Negative	Total	% (95 CI)	% (95 CI)	% (95 CI)	k (95% CI)
(C) BioMérieux VidasIII anti-SARS-CoV-2 IgG
Positive	151	9	160	93.2% (90.2–95.3%)	89.3% (83.8–93.2%)	96.0% (92.6–97.9%)	0.86 (0.82–0.90)
Negative	18	216	234
Total	169	225	394

CI confidence interval.